Cara's most advanced drug candidate in development, CR845, is a highly specific kappa opioid agonist with physical properties that ensure an unprecedented level of selectivity for kappa receptors on peripheral nerves.

Cara is developing lead molecules that selectively modulate peripheral CB receptors. CB receptors are found predominantly in peripheral tissues, particularly immune cells such as leukocytes and mast cells, which have been shown to be involved in pain and inflammatory responses.

Cara's screening technology, referred to as GPCR DimerScreen™, is designed to specifically and selectively identify molecules interacting with GPCR dimers and thus allows for the discovery of compounds with new pharmacological properties at identified dimeric drug targets.